VENTOLIN® MDI

100 µgsalbutamol

VENTOLIN®

DISKUS®

200 µgsalbutamol

AIROMIR®

MDI

100 µgsalbutamol

Short-acting bronchodilators

ONBREZ®

BREEZHALER®

75 µgindacaterol maleate

SEREVENT® DISKUS®

50 µgsalmeterol xinafoate

OXEZE® TURBUHALER®

6 µg • 12 µgformoterol fumarate

Long-acting bronchodilators

SEEBRI® BREEZHALER®

50 μg glycopyrronium

SPIRIVA® RESPIMAT®

2,5 μg tiotropium bromide

INCRUSE® ELLIPTA®

62,5 μg umeclidinium

TUDORZA® GENUAIR®

400 μgaclidinium bromide

SPIRIVA®

HANDIHALER®

18 μgtiotropium bromide

Long-acting muscarinic antagonist

COMBIVENT®

RESPIMAT®

20/100 μgIpratropium bromide and salbutamol

Combination medication (short-acting muscarinic antagonist and short-acting bronchodilator)

ATROVENT ®

MDI

20 µgipratropium bromide

Short-acting muscarinic antagonist

COPD involves two respiratory problems, i.e. chronic bronchitis and emphysema. These two conditions cause a gradual obstruction of the respiratory tract. Afflicted individuals may suffer from either of the two illnesses or both at the same time.

Sufferers may exhibit one or several of the following symptoms:

•Shortness of breath•Chronic cough•Secretions (mucus)

Chronic bronchitis is characterized by permanent bronchial inflamma-tion and excessive production of mucus, which hampers the flow of air to the lungs.

Emphysema affects the alveoli of the lungs. It causes dilation of the alveoli and destruction of the alveolar walls. The air remains trapped in the damaged alveoli, thus making it difficult to breathe. Gaseous exchanges are also affected by the destruction of the alveolar tissue.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

SIGNS AND SYMPTOMS

EMPHYSEMACHRONIC BRONCHITIS

INHALATION CHAMBER

Did you know that inhalers used without an inhalation chamber propel only 10% of the medication into the lungs and that almost 80% of the medication is simply deposited in the mouth? All inhalers should be used with an inhalation chamber. As a result, you will:•Optimize the administration of the drug (better deposition, better synchronization and simpler technique);•Reduce the side effects of certain drugs.

Selected list of controllers

BRICANYL®

TURBUHALER®

0.5 mgterbutaline sulfate

Normal airway Normal airway

Inflammation

Mucus

Damaged alveoli

Chronic bronchitis Emphysème

FLOVENT® MDI

50 µg • 125 µg 250 µgfluticasone propionate

PULMICORT® TURBUHALER®

100 µg • 200 µg 400 µgbudesonide

Inhaled corticosteroids

FLOVENT® DISKUS®

50 µg • 100 µg 250 µg • 500 µgfluticasone propionate

BREO® ELLIPTA®

100/25 µgfluticasone furoate and vilanterol

ADVAIR®

MDI

125/25 µg 250/25 µgfluticasone propionate and salmeterol

SYMBICORT®

TURBUHALER®

100/6 µg • 200/6 µgbudesonide and formoterol fumarate

Combination medications (inhaled corticosteroids and long-acting bronchodilators)

ADVAIR® DISKUS®

100/50 µg • 250/50 µg 500/50 µgfluticasone propionate and salmeterol

ANORO®

ELLIPTA®

62.5/25 µgumeclidinium and vilanterol

ULTIBRO® BREEZHALER®

50/110 µgglycopyrronium and indacaterol maleate

DUAKLIR® GENUAIR®

400/12 μgaclidinium bromide and formoterol fumarate

INSPIOLTO® RESPIMAT®

2,5/2,5 μgtiotropium bromide and olodaterol hydrochloride

Combination medications (Long-acting muscarinic antagonist and long-acting bronchodilators)

•Increasingly frequent respiratory infections and slower recovery•Fatigue•Reduced ability to pursue everyday activities

COPDMEDICATIONS CHART

Selected list of relievers

Head office : 6070 Sherbrooke Street East, office 104Montreal (Quebec) H1N 1C1www.pq.lung.ca